133 related articles for article (PubMed ID: 27587582)
1. Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I.
Peter S; Yu H; Ivanyi-Nagy R; Dröge P
Nucleic Acids Res; 2016 Dec; 44(22):e162. PubMed ID: 27587582
[TBL] [Abstract][Full Text] [Related]
2. A rapid and sensitive high-throughput screening method to identify compounds targeting protein-nucleic acids interactions.
Alonso N; Guillen R; Chambers JW; Leng F
Nucleic Acids Res; 2015 Apr; 43(8):e52. PubMed ID: 25653160
[TBL] [Abstract][Full Text] [Related]
3. The FGFR inhibitor PD173074 binds to the C-terminus of oncofetal HMGA2 and modulates its DNA-binding and transcriptional activation functions.
Ahmed SM; Ragunathan P; Shin J; Peter S; Kleissle S; Neuenschwander M; Schäfer R; Kries JPV; Grüber G; Dröge P
FEBS Lett; 2023 Aug; 597(15):1977-1988. PubMed ID: 37259564
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity.
Capranico G; Marinello J; Baranello L
Biochim Biophys Acta; 2010 Dec; 1806(2):240-50. PubMed ID: 20600630
[TBL] [Abstract][Full Text] [Related]
5. The chromatin structuring protein HMGA2 influences human subtelomere stability and cancer chemosensitivity.
Ahmed SM; Ramani PD; Wong SQR; Zhao X; Ivanyi-Nagy R; Leong TC; Chua C; Li Z; Hentze H; Tan IB; Yan J; DasGupta R; Dröge P
PLoS One; 2019; 14(5):e0215696. PubMed ID: 31067275
[TBL] [Abstract][Full Text] [Related]
6. Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.
Ahmed SM; Dröge P
Mol Oncol; 2019 Oct; 13(10):2062-2078. PubMed ID: 31271486
[TBL] [Abstract][Full Text] [Related]
7. Transactivation functions of the tumor-specific HMGA2/LPP fusion protein are augmented by wild-type HMGA2.
Crombez KR; Vanoirbeek EM; Van de Ven WJ; Petit MM
Mol Cancer Res; 2005 Feb; 3(2):63-70. PubMed ID: 15755872
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of high-mobility-group A2 protein binding to DNA by netropsin: a biosensor-surface plasmon resonance assay.
Miao Y; Cui T; Leng F; Wilson WD
Anal Biochem; 2008 Mar; 374(1):7-15. PubMed ID: 18023407
[TBL] [Abstract][Full Text] [Related]
9. Nascent DNA Proteomics Reveals a Chromatin Remodeler Required for Topoisomerase I Loading at Replication Forks.
Ribeyre C; Zellweger R; Chauvin M; Bec N; Larroque C; Lopes M; Constantinou A
Cell Rep; 2016 Apr; 15(2):300-9. PubMed ID: 27050524
[TBL] [Abstract][Full Text] [Related]
10. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
Prada CF; Alvarez-Velilla R; Balaña-Fouce R; Prieto C; Calvo-Álvarez E; Escudero-Martínez JM; Requena JM; Ordóñez C; Desideri A; Pérez-Pertejo Y; Reguera RM
Biochem Pharmacol; 2013 May; 85(10):1433-40. PubMed ID: 23466420
[TBL] [Abstract][Full Text] [Related]
11. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation.
Boo LM; Lin HH; Chung V; Zhou B; Louie SG; O'Reilly MA; Yen Y; Ann DK
Cancer Res; 2005 Aug; 65(15):6622-30. PubMed ID: 16061642
[TBL] [Abstract][Full Text] [Related]
12. HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB.
Cleynen I; Brants JR; Peeters K; Deckers R; Debiec-Rychter M; Sciot R; Van de Ven WJ; Petit MM
Mol Cancer Res; 2007 Apr; 5(4):363-72. PubMed ID: 17426251
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
14. Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor.
Shin WS; Han J; Kumar R; Lee GG; Sessler JL; Kim JH; Kim JS
Sci Rep; 2016 Jul; 6():29018. PubMed ID: 27374023
[TBL] [Abstract][Full Text] [Related]
15. Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays.
Su L; Bryan N; Battista S; Freitas J; Garabedian A; D'Alessio F; Romano M; Falanga F; Fusco A; Kos L; Chambers J; Fernandez-Lima F; Chapagain PP; Vasile S; Smith L; Leng F
Sci Rep; 2020 Nov; 10(1):18850. PubMed ID: 33139812
[TBL] [Abstract][Full Text] [Related]
16. Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction.
Wu Y; Wang KY; Li Z; Liu YP; Izumi H; Uramoto H; Nakayama Y; Ito K; Kohno K
J Exp Clin Cancer Res; 2014 Dec; 33(1):112. PubMed ID: 25539742
[TBL] [Abstract][Full Text] [Related]
17. Human HMGA2 promoter is coregulated by a polymorphic dinucleotide (TC)-repeat.
Borrmann L; Seebeck B; Rogalla P; Bullerdiek J
Oncogene; 2003 Feb; 22(5):756-60. PubMed ID: 12569368
[TBL] [Abstract][Full Text] [Related]
18. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.
Pommier Y
Semin Oncol; 1996 Feb; 23(1 Suppl 3):3-10. PubMed ID: 8633251
[TBL] [Abstract][Full Text] [Related]
20. The high mobility group protein HMGA2: a co-regulator of chromatin structure and pluripotency in stem cells?
Pfannkuche K; Summer H; Li O; Hescheler J; Dröge P
Stem Cell Rev Rep; 2009 Sep; 5(3):224-30. PubMed ID: 19551524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
